Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...
A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...
The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...
Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...
BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Hosted on MSN
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...
Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby contains the active ingredient ...
Attruby’s (acoramidis) dosage for transthyretin amyloid cardiomyopathy is typically two tablets twice per day. Your dosing schedule may vary based on factors such as your symptoms and other ...
Attruby (acoramidis) can cause certain side effects, including diarrhea and pain in the upper abdomen. Serious side effects haven’t been reported with Attruby. If you experience side effects that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results